Research and Markets: Bisphosphonates Update - The Treatment and Prevention of Bone Metastases in Breast and Prostate Cancer.DUBLIN, Ireland -- New Treatment Imminent For Bone Metastases bone metastases Oncology Cancer that has spread from a primary tumor to the bone In Breast And Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. Research and Markets (http://www.researchandmarkets.com) has announced the addition of Bisphosphonates Update - The Treatment and Prevention of Bone Metastases in Breast and Prostate Cancer to their offering. Introduction Metastases Metastasis (plural, metastases) A tumor growth or deposit that has spread via lymph or blood to an area of the body remote from the primary tumor. Mentioned in: Malignant Melanoma to the bone occur in up to 75% of patients with breast and prostate cancer and can severely affect quality of life. This Brief examines trends in the bone metastases market for both prostate and breast cancer, the potential of the drugs for cancer-related osteoporosis osteoporosis (ŏs'tēō'pərō`sĭs), disorder in which the normal replenishment of old bone tissue is severely disrupted, resulting in weakened bones and increased risk of fracture; osteopenia and what pharmaceutical companies need to do to consolidate their positions in the market. Scope: Overview of treatment of bone metastases in breast and prostate cancer Potential of bisphosphonates in the osteoporosis market Clinical application of bisphosphonates in adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant) 1. assisting or aiding. 2. a substance that aids another, such as an auxiliary remedy. 3. setting Opinions from leading physicians in the field of bisphosphonates Report Highlights: Novartis' Zometa will overtake o·ver·take tr.v. o·ver·took , o·ver·tak·en , o·ver·tak·ing, o·ver·takes 1. a. To catch up with; draw even or level with. b. To pass after catching up with. 2. Aredia as the gold standard treatment for bone metastases imminently The use of Zometa in combination with anti-aromatase agents will be the key to Novartis' expansion in the bone metastases market There is significant potential of bisphosphonates in the treatment of hormonal therapy-induced osteoporosis, especially in the prostate cancer market Reasons to Purchase: Predict the commercial potential of bisphosphonates for osteoporosis to determine the viability of entry into the market Determine the possible clinical applications of bisphosphonates and maximize the full market potential of your product Enhance your commercial positioning by understanding the cost-effectiveness of bisphosphonate therapy for bone metastases Report Contents: DRIVERS & TRENDS Novartis' Zometa (zoledronate) is likely to supersede To obliterate, replace, make void, or useless. Supersede means to take the place of, as by reason of superior worth or right. A recently enacted statute that repeals an older law is said to supersede the prior legislation. Aredia (pamidronate), also from Novartis, as the gold-standard therapy for the treatment of bone metastases imminently What are the advantages of Zometa over Aredia? How significant will the results of Z-FAST be to Novartis' strategy in the breast cancer market? BONE METASTASES The skeleton skeleton, in anatomy skeleton, in anatomy, the stiff supportive framework of the body. The two basic types of skeleton found among animals are the exoskeleton and the endoskeleton. is the most common site of recurrence recurrence /re·cur·rence/ (-ker´ens) the return of symptoms after a remission.recur´rent re·cur·rence n. 1. of metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer, and bone metastases will occur in 65% to 75% of patients with metastatic breast cancer during their lifetime What are the risk factors for developing bone metastases? What are the different mechanisms of bone metastases? CURRENTLY MARKETED DRUGS Despite the dominance of Zometa and Aredia in the bone metastases market, there is significant opportunity for clodronate to enter the US market What are the reasons for the potential uptake uptake /up·take/ (up´tak) absorption and incorporation of a substance by living tissue. up·take n. of clodronate in the US? Why is clodronate more commonly used in some countries than Zometa? POTENTIAL CLINICAL APPLICATIONS Prevention of bone metastases and treatment of osteoporosis will be the key to the expansion of the bisphosphonate market. What are the opinion leader views on bisphosphonates' potential in adjuvant setting? How efficacious ef·fi·ca·cious adj. Producing or capable of producing a desired effect. See Synonyms at effective. [From Latin effic is the treatment of osteoporosis in prostate cancer? ACTION POINTS Action point 1 - The use of bisphosphonates in the adjuvant setting remains controversial due to conflicting results in clinical trials. More studies to determine the efficacy and cost-effectiveness of adjuvant bisphosphonates are needed to gain wider acceptance Action point 2 - Clodronate remains unavailable in the US despite numerous clinical studies involving the drug for the treatment and prevention of bone metastases. This represents a significant opportunity for Schering AG, the marketer of clodronate in Europe, and generic companies marketing clodronate to enter the US bone metastases market Action point 3 - Datamonitor believes that there is significant potential of bisphosphonates in the treatment of hormonal therapy-induced osteoporosis, especially in the prostate cancer market. However, cost is expected to be a major issue in the uptake of the drugs in the European markets Action point 4 - The key to Novartis' expansion in the breast cancer market for Zometa will be the results of Z-FAST. Although the trial results will not be available for several years, Datamonitor expects the usage of Zometa with Femara (letrozole) to creep into physician prescribing due to Novartis' marketing For more information visit http://www.researchandmarkets.com/reports/c5210 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion